Clinical Trials

DermatologicGenitourinary

81 enrolled 12 charts

Urinary Bladder Neoplasms, Melanoma

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

110 enrolled 27 charts

Phase 2 Active not recruiting

Melanoma

NCT02743819 2025-06-10

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

70 enrolled 11 charts

Melanoma

NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

41 enrolled 15 charts

Melanoma, Neoplasm Metastasis

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

906 enrolled 16 charts 1 FDA

Melanoma

NCT01703507 2025-05-16

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Phase 1 Completed

17 enrolled 15 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

Phase 2 Active not recruiting

Melanoma

NCT03719131 2025-04-22

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

15 enrolled 10 charts

Melanoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

156 enrolled 11 charts

Melanoma

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT02027935 2024-10-08

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

16 enrolled 8 charts

Melanoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

4 enrolled 11 charts

Melanoma

NCT01119508 2024-06-06

Ipilimumab + Temozolomide in Metastatic Melanoma

64 enrolled 6 charts

Melanoma

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Melanoma

NCT02107755 2024-05-21

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

8 enrolled 12 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01740297 2024-05-14

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

217 enrolled 27 charts

Melanoma

NCT02970981 2024-04-30

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

18 enrolled 8 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

16 enrolled 14 charts

Melanoma

NCT01621490 2024-04-23

PD-1

Phase 1 Completed

170 enrolled 34 charts

Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

53 enrolled 10 charts

Uveal Melanoma, Melanoma

NCT02978443 2024-04-04

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

14 enrolled 12 charts

Melanoma

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

1 enrolled

Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

Melanoma

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Phase 1 Terminated

3 enrolled 5 charts

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

CNSDermatologicLymphoidSarcoma

140 enrolled 23 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT02403778 2023-09-21

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

10 enrolled 12 charts

Melanoma

NCT02658890 2023-08-28

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

627 enrolled 59 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02203604 2023-07-18

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

9 enrolled 13 charts

Melanoma

NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

47 enrolled 16 charts

Melanoma

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Phase 1 Completed

17 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02731729 2022-12-23

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

20 enrolled 19 charts